The overexpression of immune checkpoint molecules in the prostate cancer TME has led to the development of immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 therapies, which aim to restore T-cell activity and promote tumor regression. This evidence concerns the gene CTLA4 and neoplasm.